内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

Diabetologia：1型糖尿病严重程度的一种新的标志物

2020-01-30 MedSci MedSci原创

标志物1型糖尿病严重程度
关注

MicroRNAs (miRNAs)是一类新型的潜在生物标志物，可以用于许多疾病中，当然也包括1型糖尿病。在这里，我们的目标是分析一组非肥胖糖尿病(NOD)小鼠和1型糖尿病患者的循环miRNAs。

MicroRNAs (miRNAs)是一类新型的潜在生物标志物，可以用于许多疾病中，当然也包括1型糖尿病。在这里，我们的目标是分析一组非肥胖糖尿病(NOD)小鼠和1型糖尿病患者的循环miRNAs。

我们采用标准化的方法从小样本中提取miRNAs，以评估配对血浆和激光捕获的微切割免疫浸润胰岛中成熟的miRNAs。此外，我们在NOD小鼠以及1型糖尿病患者的疾病进展和抗cd3治疗缓解期验证了这一发现。

糖尿病小鼠与正常血糖小鼠血浆中5种miRNAs的水平降低。其中，miR-409-3p在糖尿病小鼠免疫胰岛浸润中下调，提示其与疾病发病机制有关。靶预测工具将miR-409-3p与免疫和代谢相关的信号分子联系起来。原位miR-409-3p表达与insulitis严重程度相关，CD8+中央记忆T细胞在miR-409-3p中富集。血浆miR-409-3p水平在糖尿病发展过程中逐渐降低，在抗cd3抗体治疗后随病情缓解而改善。最后，与非糖尿病对照组相比，新近诊断为1型糖尿病的患者血浆miR-409-3p水平较低，且与糖化血红蛋白水平呈负相关。

因此，我们认为miR-409-3p可能是胰岛炎症和1型糖尿病严重程度的一种新的循环生物标志物。

原始出处：

Giuliana Ventriglia,Francesca Mancarella,miR-409-3p is reduced in plasma and islet immune infiltrates of NOD diabetic mice and is differentially expressed in people with type 1 diabetes

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1639340, encodeId=49711639340f1, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 12 18:08:00 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761303, encodeId=5c671e6130350, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jan 02 12:08:00 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841469, encodeId=c9de1841469e3, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Mar 09 18:08:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042947, encodeId=876f104294e28, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Jan 31 02:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=)]
    2020-07-12 ms9608593228839890

    #DIA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1639340, encodeId=49711639340f1, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 12 18:08:00 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761303, encodeId=5c671e6130350, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jan 02 12:08:00 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841469, encodeId=c9de1841469e3, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Mar 09 18:08:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042947, encodeId=876f104294e28, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Jan 31 02:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=)]
    2021-01-02 ms5439512287675881

    #BET#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1639340, encodeId=49711639340f1, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 12 18:08:00 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761303, encodeId=5c671e6130350, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jan 02 12:08:00 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841469, encodeId=c9de1841469e3, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Mar 09 18:08:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042947, encodeId=876f104294e28, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Jan 31 02:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=)]
    2020-03-09 hukaixun

    #标志物#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1639340, encodeId=49711639340f1, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 12 18:08:00 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761303, encodeId=5c671e6130350, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jan 02 12:08:00 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841469, encodeId=c9de1841469e3, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Mar 09 18:08:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042947, encodeId=876f104294e28, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Jan 31 02:08:00 CST 2020, time=2020-01-31, status=1, ipAttribution=)]
    2020-01-31 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Eur Heart J：肾小管功能标志物与心血管事件和死亡风险

由此可见，在患有CKD的非糖尿病患者中，肾小管功能的生物标志物与CVD事件和死亡率相关，而与肾小球功能和白蛋白尿无关。

Diabetes Care：氧化应激血清标志物与2型糖尿病患者的主要心血管事件、癌症发病率和全因死亡率的关联

由此可见，氧化应激生物标志物与死亡率之间的强烈关联表明不平衡的氧化还原系统会促进糖尿病患者的过早死亡。

Neurology：CD14与痴呆和大脑衰老和损伤标志物有关

由此可见，sCD14作为炎性标记物，与脑萎缩、认知能力下降和事件性痴呆有关。

JACC：老年人心血管事件的风险标志物

随着年龄增长，心血管风险急剧增加，导致老年人群中几乎普遍存在基于风险的他汀类药物资格。为限制过度治疗，需确定真正低风险的老年人。JACC发表的一项研究旨在发现“负”风险标志物，以识别低短期风险的冠心病和心血管疾病老年人。

Clinica Chimica Acta：硫酸盐结合胆固醇代谢物作为C型尼曼-皮克病尿生物标志物的诊断性能评价

尼曼

复发/转移性乳腺癌标志物临床应用专家共识（2019年版）

在个体化精准医学时代，包括组织活检和液体活检在内的肿瘤生物标志物检测在辅助制定复发/转移性乳腺癌的治疗方案和疗效监测中尤为重要，但目前其在临床诊疗应用中还缺乏统一的认识。为规范使用肿瘤生物标志物监测结果，中国抗癌协会肿瘤标志专业委员会乳腺癌标志物协作组和中国抗癌协会肿瘤标志专业委员会遗传性肿瘤标志物协作组组织相关专家，综合复发/转移性乳腺癌生物标志物检测领域的指南、共识、重要文献及我国临床实践，编